MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.74
-2.15
-10.81%
After Hours: 17.74 0 0.00% 16:00 02/27 EST
OPEN
19.51
PREV CLOSE
19.89
HIGH
19.76
LOW
17.70
VOLUME
287.59K
TURNOVER
--
52 WEEK HIGH
25.07
52 WEEK LOW
8.13
MARKET CAP
570.53M
P/E (TTM)
-4.7142
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ASMB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ASMB stock price target is 41.25 with a high estimate of 74.00 and a low estimate of 25.00.

EPS

ASMB News

More
  • Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know
  • Zacks · 02/20 17:31
  • Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
  • GlobeNewswire · 02/19 13:00
  • Does The Assembly Biosciences, Inc. (NASDAQ:ASMB) Share Price Tend To Follow The Market?
  • Simply Wall St. · 01/28 11:00
  • Biotech Bonanza: 2020 Outlook In An Election Year
  • Seeking Alpha - Article · 01/08 21:15

Industry

Pharmaceuticals
-2.62%
Pharmaceuticals & Medical Research
-2.52%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ASMB

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
More

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.